Download Our StacheStrong Deck to Learn More and Explore Sponsorship Opportunities

Explore Sponsorship Opportunities

Hoodline Covers Colin Gerner’s $1 Million Fight Against Glioblastoma at the Boston Marathon

hoodline-colin-gerner-boston-marathon-for-brain-cancer-research-glioblastoma-stachestrong

StacheStrong’s Boston Marathon story continues to make headlines. This April, Hoodline published a feature on Colin Gerner and the mission driving every mile he runs, covering the five-year, $1 million research commitment that makes this year’s race one of the most significant in StacheStrong’s history. Read the original article: Hoboken Runner Turns Boston Marathon Into […]

StacheStrong Featured on the AACR Podcast: “From Mustache to Mission: How StacheStrong Is Changing Brain Cancer Research”

StacheStrong has been featured on Believe in Progress, the official podcast of the American Association for Cancer Research (AACR) Foundation. The episode, titled “From Mustache to Mission: How StacheStrong Is Changing Brain Cancer Research,” features Colin Gerner in conversation with host Mitch Stoller, telling the full story of StacheStrong from its deeply personal beginnings to […]

Brain Cancer Research in the Spotlight: StacheStrong Featured on NBC Boston

This April, StacheStrong was featured on NBC Boston’s Morning Boost segment ahead of the 2026 Boston Marathon. The segment shone a light on Colin Gerner, President, CEO and Co-Founder of StacheStrong, and the remarkable story behind why he was running one of the world’s most iconic races. It is a story rooted in loss, love, […]

The V Foundation for Cancer Research and StacheStrong Announce $1 Million, Five-Year Grant Award to Advance Glioblastoma Research 

V-Foundation-x-StacheStrong-Lockup-cover

Cary, NC (March 23, 2026) –The V Foundation for Cancer Research and StacheStrong, two top-rated charities dedicated to funding innovative cancer research, announced a transformative $1 million, five-year grant award at Massachusetts General Hospital to accelerate research focused on glioblastoma (GBM), the most common and aggressive form of brain cancer.  This long-term investment represents a […]